Skip to content
Evigrade
MinorDrugs for peptic ulcer and GORD. Proton pump inhibitors×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

About two thirds of a rivaroxaban dose is metabolised in the liver by CYP3A4, CYP2J2 and CYP-independent pathways, and the rest is excreted unchanged by the kidneys. Its elimination also depends on the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (rivaroxaban SmPC, European Medicines Agency, EMA). Esomeprazole inhibits CYP2C19 and lowers gastric acidity, so it changes the levels of drugs cleared by CYP2C19 and the absorption of drugs that need an acid stomach (esomeprazole SmPC). Rivaroxaban belongs to neither group. With omeprazole, of which esomeprazole is an enantiomer, no clinically significant pharmacokinetic or pharmacodynamic interaction was seen, and drugs that alter gastric pH did not affect rivaroxaban pharmacokinetics (rivaroxaban SmPC, EMA; Xarelto label, US Food and Drug Administration, FDA). The table of the 2021 European Heart Rhythm Association (EHRA) practical guide lists "no effect" for rivaroxaban with proton pump inhibitors.

Symptoms

The documents describe no symptoms linked to this combination. The main risk of rivaroxaban is bleeding, most often from mucosa: nosebleeds and gum, gastrointestinal and genitourinary bleeding, including heavy menstrual bleeding, and anaemia. An unexplained fall in haemoglobin or blood pressure calls for a search for a bleeding site (rivaroxaban SmPC, European Medicines Agency, EMA). Esomeprazole can relieve the symptoms of gastric cancer and delay its diagnosis, so with vomiting of blood, black stools, unexplained weight loss or difficulty swallowing, malignancy is ruled out (esomeprazole SmPC). After more than three months of esomeprazole, severe hypomagnesaemia with fatigue, seizures, dizziness and ventricular arrhythmia can occur (esomeprazole SmPC).

Management

According to the documents, the combination is acceptable, and the doses of rivaroxaban and esomeprazole need no change. No clinically significant interaction was found with the proton pump inhibitor omeprazole (rivaroxaban SmPC, European Medicines Agency, EMA; Xarelto label, US Food and Drug Administration, FDA), and the 2021 European Heart Rhythm Association (EHRA) practical guide expects no effect of this class on rivaroxaban. If a person taking rivaroxaban is at risk of ulcer disease, prophylactic treatment may be considered (rivaroxaban SmPC, EMA). The EHRA guide suggests proton pump inhibitors to reduce the risk of gastrointestinal bleeding, especially after previous bleeding or ulcer and with concomitant antiplatelet therapy. In gastrointestinal disease without an active ulcer that may lead to bleeding complications, such as oesophagitis, gastritis or gastro-oesophageal reflux, rivaroxaban is not recommended (rivaroxaban SmPC, EMA). During rivaroxaban treatment, watch for signs of bleeding and anaemia, and interrupt rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA). Vomiting of blood and black stools are not put down to an ulcer until malignancy has been ruled out (esomeprazole SmPC).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Esomeprazole

Other interactions with Rivaroxaban